{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT00130156: Phase 4 Interventional Completed High Blood Pressure
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Bunazosin (E-643) is a quinazoline derivative with a1-adrenoceptor blocking activity. It has been clinically used both as a systemic antihypertensive as well as an ocular hypotensive drug. The major adverse effect associated with the use of bunazosin is orthostatic hypotension or its consequences (e.g. dizziness). Others adverse effects include headache, sweating, nausea, dry mouth, abdominal pain, diarrhea, and constipation. The effects of Bunazosin may be enhanced by diuretics and other antihypertensive agents and decreased by Rifampicin.
Status:
Possibly Marketed Outside US
Source:
Madar by Sternbach, L.H.|Reeder, E.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nordazepam (INN; marketed under brand names Nordaz, Stilny, Madar, Vegesan, and Calmday) is a 1,4-benzodiazepine derivative with amnesic, anticonvulsant, anxiolytic, muscle relaxant, and sedative properties. Nordazepam is an active metabolite of diazepam, chlordiazepoxide, clorazepate, prazepam, pinazepam, and medazepam, used primarily in the treatment of anxiety disorders. Nordazepam is a partial agonist at the GABAA receptor, which makes it less potent than other benzodiazepines, particularly in its amnesic and muscle-relaxing effects. Nordazepam’s elimination half-life is between 36 and 200 hours, with wide variation among individuals; factors such as age and gender are known to impact it. The variation of reported half-life are attributed to differences in nordazepam metabolism and that of its metabolites as nordazepam is hydroxylated to active metabolites such as oxazepam, before finally being glucuronidated and excreted in the urine. Common side effects of nordazepam include somnolence, which is more common in elderly patients and/or people on high-dose regimens. Hypotonia, which is much less common, is also associated with high doses and/or old age.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Buparvaquone is a second-generation hydroxynaphtaquinone with novel features that make it an effective compound for the therapy and prophylaxis of all forms of theileriosis. It has shown promising activities against Leishmania spp. and Neospora caninum infection. In combination with arteether it is effective against Babesia equi. Buparvaquone directly inhibits the respiration of Theileria parasites. Due to the inhibiting effects of theileriosis on the immune system, vaccination should be delayed until the animal has recovered from theileriosis. Localised, painless, oedematous swelling may occasionally be seen at the injection site.
Status:
Possibly Marketed Outside US
Source:
CEPRAVIN
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Cefalonium is a 1st generation cephalosporin with a broad spectrum of actvity against Gram-positive and Gram-negative bacterias. The drug inhibits the bacterial cell wall synthesis by binding to penicillin binding proteins. Cefalonium is approved for routine dry cow therapy to treat existing sub-clinical infections and to prevent new infections which occur during the dry period.
Status:
Possibly Marketed Outside US
Source:
DILOXANIDE FUROATE by The Boots
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Diloxanide (used in the form of furoate) was developed for the treatment of intestinal amoebiasis. The effectiveness of the drug was proved in clinical trials, however, the mechanism of its action is unknown. The drug is not marketed in the United States, athough it is available in India.
Status:
Possibly Marketed Outside US
Source:
NCT00892892: Phase 4 Interventional Withdrawn Chronic Kidney Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Metochalcone is a chalcone. It was isolated from heartwood of Pterocarpus marsupium. It has been approved for clinical use as choleretic and diuretic agent. It was made from 2,4-dihydroxybenzaldehyde (beta-resorcaldehide).
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Cycotiamine is a derivative of tiamine that was developed in Japan and used for the treatment of neurogenic bladder.
Status:
Possibly Marketed Outside US
Source:
FIBORAN by Manufacture de Produits Pharmaceutiques
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Aprindine is a class Ib antiarrhythmic agent. It is not approved in USA, but is available in European countries, where it is used to treat supraventricular and ventricular arrhythmias. Aprindine acts by blocking sodium voltage channels and disrupting interactions between calmodulin and prosphodiesterase.
Status:
Possibly Marketed Outside US
Source:
Azaphen by All-Union Scientific-Research Chemical-Pharmaceutical Institute
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Pipofezine (Azafen or Azaphen) is a tricyclic antidepressant (TCA) approved in Russia for the treatment of depression. It was introduced in the late 1960s and is still used today. Pipofezine has been shown to act as a potent inhibitor of the reuptake of serotonin. In addition to its antidepressant action, pipofezine has sedative effects as well, suggesting antihistamine activity. Other properties such as anticholinergic or antiadrenergic actions are less clear but are likely. The main advantage of Azafen compared with other tricyclic antidepressants is that this drug has a low toxic effect on the body, including the heart, and it does not block cholinergic receptors and does not change the activity of monoamine oxidase. The maximum concentration in the blood is reached after 1-2 hours after taking the drug. Absorbed in the gastrointestinal tract, metabolism occurs in the liver, and is excreted by Azaphene kidneys.